Janux Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JANX research report →
Range $23 – $55
Price Chart
About the company
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors.
- CEO
- David Alan Campbell
- IPO
- 2021
- Employees
- 113
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on JANX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $616.73M
- P/E
- -6.43
- PEG
- -2.35
- P/S
- 27.03
- P/B
- 0.71
- EV/EBITDA
- -6.21
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -599.26%
- Net Margin
- -428.74%
- ROE
- -10.68%
- ROIC
- -14.97%
Latest fiscal year · YoY change
- Revenue
- $10.00M-5.6%
- Gross Profit
- $7.97M-6.5%
- Op Income
- $-157,667,000
- Net Income
- $-113,625,000-64.7%
- EPS
- $-1.83-43.0%
- OCF Growth
- -87.7%
- FCF Growth
- -88.5%
- 52W High
- $35.34
- 52W Low
- $10.05
- 50D MA
- $16.10
- 200D MA
- $15.29
- Beta
- 2.39
- RSI (14)
- 26
- Avg Volume
- 952.26K
No earnings-call transcripts are available for JANX yet.
- Free Float
- 94.6%
- Shares Outstanding
- 61.18M
- Float Shares
- 57.87M
of shares held by institutions
205 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 11.19M | 0 |
| Blackrock, Inc. | 6.53M | ▲ 400.07K |
| Janus Henderson Group Ltd. | 4.20M | ▼ 1.15M |
| Prosight Management, LP | 2.94M | ▼ 861.28K |
| Vanguard Group Inc | 2.91M | ▲ 489.28K |
| Federated Hermes, Inc. | 2.59M | ▲ 241.79K |
| Fmr LLC | 2.51M | ▲ 97.26K |
| State Street Corp | 2.31M | ▼ 693.95K |
| Vanguard Capital Management LLC | 2.15M | ▲ 295.79K |
| Point72 Asset Management, L.P. | 1.99M | ▲ 837.70K |
| Tcg Crossover Management, LLC | 1.79M | 0 |
| Alyeska Investment Group, L.P. | 1.65M | ▲ 46.05K |
Held by 262 ETFs
Biggest fund positions in JANX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 31, 26 | Campbell David Alan | other | 123,840 |
| Jul 8, 26 | Campbell David Alan | other | 7,000 |
| Jul 8, 26 | Campbell David Alan | other | 7,000 |
| Jun 11, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 15,500 |
| Jun 11, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 5,500 |
| Jun 11, 26 | Simson Jake | other | 15,500 |
| Jun 11, 26 | Simson Jake | other | 5,500 |
| Jun 11, 26 | Kung Winston | other | 15,500 |
| Jun 11, 26 | Kung Winston | other | 5,500 |
| Jun 11, 26 | Hernday Natasha | other | 15,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our JANX coverage
Recent articles, reports, and earnings notes.
No research on JANX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate JANX report →Janux Therapeutics, Inc. (JANX) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy Transcript
seekingalpha.com · Nov 9
Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease
businesswire.com · Nov 9
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 5
Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
businesswire.com · Nov 5
Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
businesswire.com · Nov 2
Janux Therapeutics (NASDAQ:JANX) and Zai Lab (NASDAQ:ZLAB) Head-To-Head Survey
defenseworld.net · Oct 13
Head-To-Head Review: Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV)
defenseworld.net · Oct 6
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
zacks.com · Sep 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.